COMPASS Pathways’ (CMPS) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a report published on Tuesday, Benzinga reports.

Several other analysts also recently commented on the company. HC Wainwright reaffirmed a buy rating and set a $120.00 price objective on shares of COMPASS Pathways in a research note on Friday, March 1st. Morgan Stanley started coverage on COMPASS Pathways in a research note on Monday, April 1st. They set an overweight rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of Buy and an average target price of $47.40.

COMPASS Pathways Stock Performance

CMPS stock opened at $8.57 on Tuesday. The business’s fifty day moving average is $9.60 and its 200-day moving average is $8.46. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.14. The company has a market cap of $530.83 million, a P/E ratio of -3.59 and a beta of 2.48. COMPASS Pathways has a twelve month low of $5.01 and a twelve month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Equities research analysts forecast that COMPASS Pathways will post -2.4 EPS for the current year.

Insiders Place Their Bets

In other COMPASS Pathways news, Director Ekaterina Malievskaia sold 19,853 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total transaction of $210,243.27. Following the completion of the transaction, the director now owns 4,144,994 shares in the company, valued at approximately $43,895,486.46. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other COMPASS Pathways news, Director Ekaterina Malievskaia sold 19,853 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total transaction of $210,243.27. Following the completion of the transaction, the director now owns 4,144,994 shares in the company, valued at approximately $43,895,486.46. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder George Jay Goldsmith sold 23,881 shares of the stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total value of $203,704.93. Following the transaction, the insider now owns 3,986,523 shares of the company’s stock, valued at approximately $34,005,041.19. The disclosure for this sale can be found here. In the last 90 days, insiders sold 140,601 shares of company stock worth $1,338,911. Corporate insiders own 4.25% of the company’s stock.

Hedge Funds Weigh In On COMPASS Pathways

Large investors have recently added to or reduced their stakes in the company. Quest Partners LLC bought a new position in shares of COMPASS Pathways in the 4th quarter valued at about $33,000. Bailard Inc. bought a new position in shares of COMPASS Pathways in the 3rd quarter valued at about $88,000. Conservest Capital Advisors Inc. bought a new position in shares of COMPASS Pathways in the 4th quarter valued at about $91,000. TAP Consulting LLC grew its holdings in shares of COMPASS Pathways by 14.7% in the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock valued at $95,000 after acquiring an additional 1,645 shares in the last quarter. Finally, AE Wealth Management LLC bought a new position in shares of COMPASS Pathways in the 3rd quarter valued at about $106,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.